

# **MEDICAL LABORATORY EVALUATION**

## **PARTICIPANT SUMMARY**

**2 • 0 • 0 • 6**

**Please see the corresponding US participant summary for any statistics not represented in this supplement.**



Total Commitment to Education and Service  
Provided by ACP Services, Inc.

**International Data Supplement  
MLE – M3**

# Table of Contents

<b>2006 Evaluation Criteria</b> .....	<b>3</b>
<b>Coagulation</b>	
<b>Prothrombin Time</b> .....	4
International Normalized Ratio (INR) .....	5
<b>Activated Partial Thromboplastin Time</b> .....	7
<b>Fibrinogen</b> .....	8
<b>Urinalysis</b>	
<b>Urinalysis Dipstick</b> .....	9
Specific Gravity .....	9
pH .....	9
Protein .....	10
Glucose or Reducing Substance .....	10
Ketones.....	11
Bilirubin .....	11
Urobilinogen.....	12
Blood or Hemoglobin .....	12
Leukocyte Esterase .....	13
Nitrite .....	13
Microalbumin (Dipstick Only) .....	14
<b>Urine hcG</b> .....	14
<b>Microbiology</b>	
<b>Antimicrobial Susceptibility Testing</b> .....	15
<b>Parasitology (PA Specimens)</b> .....	16
<b>Parasitology (FP Specimens)</b> .....	17
<b>Immunology</b>	
<b>Syphilis Serology</b> .....	18
VDRL Slide .....	18
VDRL Slide (Titer).....	19
MHA-TP .....	19
FTA-ABS.....	19
RPR .....	20
RPR (Titer).....	20
<b>Viral Markers</b> .....	21
Anti-HBc.....	21
Anti-HIV .....	21
HAV .....	22
HBeAg .....	22
HBsAb.....	23
HBsAg.....	24
HCV .....	25
<b>Chemistry</b>	
<b>Total Bilirubin</b> .....	26
<b>Neonatal Bilirubin</b> .....	26
<b>Blood Gases</b> .....	27

## 2006 Evaluation Criteria

The evaluation criteria used in the 2006 MLE Program is in accordance with the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) federal requirements for proficiency testing. The criteria are included below.

### Qualitative

For qualitative procedures, evaluation is based on participant consensus. A minimum percentage of participants must receive a passing score or the challenge is not evaluated due to lack of consensus. These percentages are listed below.

Antimicrobial Susceptibility Testing	80% Consensus
Microalbumin (Semi-Quantitative)	80% Consensus
Parasite Identification	80% Consensus
Syphilis Serology	80% Consensus
Urine Dipstick	80% Consensus
Urine hCG	80% Consensus
Viral Markers	80% Consensus

### Quantitative

For quantitative procedures, a mean and standard deviation (SD) are calculated for each peer group consisting of 5 or more laboratories. Acceptable performance is established based on a target value  $\pm$  the intervals below. An explanation on how to calculate the range of acceptability based upon these limits is also provided in your MLE Program Guide on pages 39-40 under the heading "Acceptable Ranges for Quantitative Results."

Activated Partial Thromboplastin Time	$\pm$ 15 percent
Bilirubin, Neonatal (Total)	$\pm$ 0.4 mg/dL or 20% *
Bilirubin, Total	$\pm$ 0.4 mg/dL or 20% *
Calcium, Ionized	$\pm$ 3 SD
Chloride	$\pm$ 5%
Fibrinogen	$\pm$ 20 percent
pCO <sub>2</sub>	$\pm$ 5 mmHg or 8% *
pH	$\pm$ 0.04
pO <sub>2</sub>	$\pm$ 3 SD
Potassium	$\pm$ 0.5 mmol/L
Prothrombin Time	$\pm$ 15 percent
Sodium	$\pm$ 4.0 mmol/L
Specific Gravity	$\pm$ 0.010



**PROTHROMBIN TIME (seconds)**

<u>Reagent/Instruments</u>	<u>Labs</u>	<b>Specimen CG-15</b>				<u>Median</u>
		<u>Mean</u>	<u>SD</u>	<u>CV</u>		
All Method	90	29.49	6.35	21.5	28.6	
Dade Innovin						
All Coagulation Instruments	13	25.09	1.51	6.0	25.0	
Dade Thromborel S						
All Coagulation Instruments	14	36.04	2.56	7.1	36.3	
Diag Stago STA Neoplastine CI+						
RAL Clot-SP	10	36.83	1.37	3.7	37.0	
All Coagulation Instruments	12	36.50	1.46	4.0	36.5	
IL TEST PT-FIB HS PLUS						
bioMerieux Thrombotimer	4	-	-	-	37.5	
Fibrometer	3	-	-	-	40.2	
All Coagulation Instruments	14	37.73	4.72	12.5	38.8	
IL TEST PT-FIB HS						
IL ACL, all models	12	24.61	1.57	6.4	24.6	
All Coagulation Instruments	13	24.43	1.64	6.7	24.1	
IL TEST PT-FIB Recombinant						
IL ACL, all models	18	27.61	2.92	10.6	27.5	
All Coagulation Instruments	19	27.66	2.84	10.3	27.5	

**PROTHROMBIN TIME-INTERNATIONAL NORMALIZED RATIO (INR)**

<u>Reagent/Instruments</u>	<u>Labs</u>	<b>Specimen CG-11</b>				<b>Specimen CG-12</b>				
		<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	101	4.75	1.05	22.1	4.6	102	1.03	0.08	7.6	1.0
Dade Innovin										
All Coagulation Instruments	12	3.88	0.24	6.2	3.9	13	0.99	0.05	5.0	1.0
Dade Thromborel S										
All Coagulation Instruments	13	4.71	0.53	11.3	4.7	14	1.01	0.06	6.1	1.0
Diag Stago STA Neoplastine CI+										
RAL Clot-SP	10	6.15	0.36	5.8	6.2	10	1.09	0.03	2.9	1.1
All Coagulation Instruments	12	6.09	0.35	5.7	6.1	12	1.08	0.04	3.6	1.1
IL TEST PT-FIB HS PLUS										
bioMerieux Thrombotimer	5	4.80	2.05	42.7	5.5	5	1.14	0.05	4.8	1.1
All Coagulation Instruments	16	5.42	0.71	13.2	5.5	17	1.09	0.07	6.4	1.1
IL TEST PT-FIB HS										
IL ACL, all models	13	4.62	1.24	26.8	4.5	12	0.97	0.08	8.1	1.0
All Coagulation Instruments	14	4.61	1.19	25.8	4.5	13	0.97	0.08	7.7	1.0
IL TEST PT-FIB Recombinant										
IL ACL, all models	17	4.27	0.40	9.4	4.1	17	0.99	0.07	7.0	1.0
All Coagulation Instruments	18	4.33	0.47	10.9	4.3	18	0.99	0.07	6.8	1.0
PH/CMS Thromboplastin-DS										
All Coagulation Instruments	5	4.52	1.49	32.9	4.6	5	1.16	0.26	22.5	1.0

**PROTHROMBIN TIME–INTERNATIONAL NORMALIZED RATIO (INR)**

<u>Reagent/Instruments</u>	<b>Specimen CG-13</b>					<b>Specimen CG-14</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	101	1.37	0.16	11.7	1.4	98	1.01	0.08	8.4	1.0
Dade Innovin										
All Coagulation Instruments	13	1.25	0.07	5.3	1.3	13	1.00	0.07	7.1	1.0
Dade Thromborel S										
All Coagulation Instruments	13	1.25	0.10	8.4	1.2	13	0.95	0.05	5.5	0.9
Diag Stago STA Neoplastine CI+										
RAL Clot-SP	10	1.47	0.07	4.6	1.5	10	0.99	0.03	3.2	1.0
All Coagulation Instruments	12	1.44	0.09	6.2	1.5	12	0.98	0.05	4.6	1.0
IL TEST PT-FIB HS PLUS										
bioMerieux Thrombotimer	5	1.48	0.28	18.7	1.6	5	1.06	0.09	8.4	1.0
All Coagulation Instruments	17	1.49	0.23	15.7	1.5	16	1.03	0.08	7.7	1.0
IL TEST PT-FIB HS										
IL ACL, all models	13	1.40	0.17	12.0	1.4	13	1.00	0.10	10.0	1.0
All Coagulation Instruments	14	1.41	0.16	11.6	1.4	14	1.01	0.10	9.9	1.0
IL TEST PT-FIB Recombinant										
IL ACL, all models	17	1.44	0.09	6.5	1.4	17	1.10	0.09	8.5	1.1
All Coagulation Instruments	18	1.44	0.09	6.4	1.4	18	1.11	0.10	9.2	1.1
PH/CMS Thromboplastin-DS										
All Coagulation Instruments	5	1.46	0.50	34.5	1.3	4	-	-	-	1.1
<b>Specimen CG-15</b>										
All Method	101	1.37	0.16	11.7	1.4					
Dade Innovin										
All Coagulation Instruments	13	1.25	0.07	5.3	1.3					
Dade Thromborel S										
All Coagulation Instruments	13	1.25	0.10	8.4	1.2					
Diag Stago STA Neoplastine CI+										
RAL Clot-SP	10	1.47	0.07	4.6	1.5					
All Coagulation Instruments	12	1.44	0.09	6.2	1.5					
IL TEST PT-FIB HS PLUS										
bioMerieux Thrombotimer	5	1.48	0.28	18.7	1.6					
All Coagulation Instruments	17	1.49	0.23	15.7	1.5					
IL TEST PT-FIB HS										
IL ACL, all models	13	1.40	0.17	12.0	1.4					
All Coagulation Instruments	14	1.41	0.16	11.6	1.4					
IL TEST PT-FIB Recombinant										
IL ACL, all models	17	1.44	0.09	6.5	1.4					
All Coagulation Instruments	18	1.44	0.09	6.4	1.4					
PH/CMS Thromboplastin-DS										
All Coagulation Instruments	5	1.46	0.50	34.5	1.3					



**ACTIVATED PARTIAL THROMBOPLASTIN (seconds)****Specimen CG-15**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	83	54.5	9.1	16.7	52
Dade Actin FS					
All Coagulation Instruments	5	82.0	13.8	16.8	73
Dade Actin FSL					
All Coagulation Instruments	12	55.3	8.6	15.6	53
Dade Actin					
All Coagulation Instruments	5	62.4	6.7	10.8	64
IL TEST APTT-SP					
IL ACL, all models	23	50.7	2.9	5.7	50
All Coagulation Instruments	41	50.1	5.7	11.3	50

**FIBRINOGEN (mg/dL)****Specimen CG-11****Specimen CG-12**

<u>Reagent/Instruments</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	52	311.2	71.3	22.9	289	44	200.6	36.8	18.3	190
Dade Fibrinogen Set										
All Coagulation Instruments	10	271.4	62.0	22.9	256	5	231.4	21.2	9.2	237
IL TEST PT Fibrinogen										
IL ACL, all models	5	289.8	42.6	14.7	294	5	161.8	21.5	13.3	164
IL TEST PT-FIB HS										
IL ACL, all models	12	388.4	58.2	15.0	408	10	177.7	13.4	7.6	175
IL TEST PT-FIB Recombinant										
IL ACL, all models	11	312.3	42.2	13.5	289	12	184.2	17.1	9.3	186

**Specimen CG-13****Specimen CG-14**

All Method	52	172.1	21.7	12.6	175	46	419.0	60.8	14.5	427
Dade Fibrinogen Set										
All Coagulation Instruments	10	163.0	19.6	12.0	170	9	438.0	49.6	11.3	427
IL TEST PT Fibrinogen										
IL ACL, all models	5	176.4	22.6	12.8	184	5	349.0	39.7	11.4	361
IL TEST PT-FIB HS										
IL ACL, all models	12	171.8	15.3	8.9	178	12	437.0	59.6	13.6	448
IL TEST PT-FIB Recombinant										
IL ACL, all models	13	185.6	21.5	11.6	192	10	395.0	47.8	12.1	396

**Specimen CG-15**

All Method	45	295.2	56.7	19.2	292
Dade Fibrinogen Set					
All Coagulation Instruments	9	248.2	37.6	15.1	253
IL TEST PT Fibrinogen					
IL ACL, all models	5	311.6	34.5	11.1	330
IL TEST PT-FIB HS					
IL ACL, all models	7	365.7	25.3	6.9	370
IL TEST PT-FIB Recombinant					
IL ACL, all models	11	310.0	37.9	12.2	298

# Urinalysis

## URINALYSIS DIPSTICK–SPECIFIC GRAVITY

### Specimen UA-3

<u>Method</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	89	1.0130	0.0046	0.5	1.010
Bayer Clinitek 50	6	1.0108	0.0021	0.2	1.010
Bayer Clinitek 500	18	1.0122	0.0026	0.3	1.010
Bayer Clinitek Atlas	5	1.0180	0.0045	0.4	1.020
Bayer Reagent Strips	6	1.0100	0.0000	0.0	1.010
Roche (BMC) Chemstrips	24	1.0115	0.0035	0.3	1.010
Roche Urisys	8	1.0159	0.0054	0.5	1.018

## URINALYSIS DIPSTICK–pH

### Specimen UA-3

### Participant Results

<u>Method</u>	<u>3.5 or less</u>	<u>4.0</u>	<u>5.0</u>	<u>5.5</u>	<u>6.0</u>	<u>6.5</u>	<u>7.0</u>	<u>7.5</u>	<u>8.0</u>	<u>8.5</u>	<u>9.0</u>
ALL METHODS	-	-	1	-	-	-	6	13	73	3	-
Arkray Aution Jet	-	-	-	-	-	-	-	-	1	-	-
Arkray Aution Sticks	-	-	-	-	-	-	-	1	2	-	-
Bayer Clinitek 50	-	-	-	-	-	-	1	-	5	-	-
Bayer Clinitek 500	-	-	-	-	-	-	-	3	15	2	-
Bayer Clinitek Atlas	-	-	-	-	-	-	-	2	3	-	-
Bayer Clinitek Status	-	-	-	-	-	-	-	-	-	1	-
Bayer Reagent Strips	-	-	-	-	-	-	-	2	5	-	-
BioScan Reagent Strips	-	-	-	-	-	-	-	-	1	-	-
Quidel QuickVue UrinChek	-	-	1	-	-	-	-	-	-	-	-
Roche (BMC) Chemstrips	-	-	-	-	-	-	3	1	20	-	-
Roche (BMC) Criterion Analyzer	-	-	-	-	-	-	-	-	3	-	-
Roche (BMC) Mini UA	-	-	-	-	-	-	-	-	1	-	-
Roche Mditron	-	-	-	-	-	-	-	-	1	-	-
Roche Urisys	-	-	-	-	-	-	-	-	8	-	-
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	-	-	-	-	3	-	-
Thermo BioStar PocketChem UA	-	-	-	-	-	-	-	-	2	-	-
UriScan Reagent Strips	-	-	-	-	-	-	1	2	1	-	-

## URINALYSIS DIPSTICK–PROTEIN QUALITATIVE

### Specimen UA-3

<u>Method</u>	<i>Participant Results</i>					
	<u>Negative</u>	<u>Trace</u>	<u>30mg/dL (1+)</u>	<u>100 mg/dL (2+)</u>	<u>300-500mg/dL (3+)</u>	<u>≥1000mg/dL (4+)</u>
ALL METHODS	90	4	2	1	-	-
Arkray Aution Jet	1	-	-	-	-	-
Arkray Aution Sticks	3	-	-	-	-	-
Bayer Clinitek 50	6	-	-	-	-	-
Bayer Clinitek 500	20	-	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-	-
Bayer Reagent Strips	6	1	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-	-
Roche (BMC) Chemstrips	25	-	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-	-
Roche (BMC) Mini UA	1	-	-	-	-	-
Roche Mditron	1	-	-	-	-	-
Roche Urisys	8	-	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	3	-	-	-	-	-
Thermo BioStar PocketChem UA	1	-	-	1	-	-
UriScan Reagent Strips	1	2	1	-	-	-

## URINALYSIS DIPSTICK–GLUCOSE OR REDUCING SUBSTANCE

### Specimen UA-3

<u>Method</u>	<i>Participant Results</i>							
	<u>Negative</u>	<u>50-100 mg/dL (Trace)</u>	<u>150 mg/dL</u>	<u>250 mg/dL</u>	<u>500 mg/dL</u>	<u>1000 mg/dL</u>	<u>&gt;1000 mg/dL</u>	<u>≥2000 mg/dL</u>
ALL METHODS	93	3	-	-	1	-	-	-
Arkray Aution Jet	1	-	-	-	-	-	-	-
Arkray Aution Sticks	1	2	-	-	-	-	-	-
Bayer Clinitek 50	6	-	-	-	-	-	-	-
Bayer Clinitek 500	20	-	-	-	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-	-	-	-
Bayer Reagent Strips	7	-	-	-	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-	-	-	-
Quidel QuickVue UrinChek	-	-	-	-	1	-	-	-
Roche (BMC) Chemstrips	25	-	-	-	-	-	-	-
Roche (BMC) Criterion Analyzer	3	-	-	-	-	-	-	-
Roche (BMC) Mini UA	1	-	-	-	-	-	-	-
Roche Mditron	1	-	-	-	-	-	-	-
Roche Urisys	8	-	-	-	-	-	-	-
Roche(BMC) SuperUA/ChemstripUA	3	-	-	-	-	-	-	-
Thermo BioStar PocketChem UA	2	-	-	-	-	-	-	-
UriScan Reagent Strips	3	1	-	-	-	-	-	-

## URINALYSIS DIPSTICK–KETONES

### Specimen UA-3

#### Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace (5 mg/dL)</u>	<u>Small (1+, 15 mg/dL)</u>	<u>Moderate (2+, 40 mg/dL)</u>	<u>Large (3+, 80 mg/dL)</u>
ALL METHODS	7	-	-	4	85
Arkray Aution Jet	-	-	-	-	1
Arkray Aution Sticks	-	-	-	-	3
Bayer Clinitek 50	-	-	-	-	6
Bayer Clinitek 500	1	-	-	1	18
Bayer Clinitek Atlas	-	-	-	-	5
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	-	-	-	-	7
BioScan Reagent Strips	-	-	-	-	1
Roche (BMC) Chemstrips	2	-	-	2	21
Roche (BMC) Criterion Analyzer	1	-	-	-	2
Roche (BMC) Mini UA	-	-	-	-	1
Roche Mditron	-	-	-	-	1
Roche Urisys	2	-	-	-	6
Roche(BMC) SuperUA/ChemstripUA	1	-	-	1	1
Thermo BioStar PocketChem UA	-	-	-	-	2
UriScan Reagent Strips	-	-	-	-	4

## URINALYSIS DIPSTICK–BILIRUBIN

### Specimen UA-3

#### Participant Results

<u>Method</u>	<u>Negative</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	12	27	47	10
Arkray Aution Jet	-	-	1	-
Arkray Aution Sticks	-	-	3	-
Bayer Clinitek 50	-	-	2	4
Bayer Clinitek 500	1	-	19	-
Bayer Clinitek Atlas	-	-	4	1
Bayer Clinitek Status	-	-	-	1
Bayer Reagent Strips	2	-	5	-
BioScan Reagent Strips	1	-	-	-
Quidel QuickVue UrinChek	1	-	-	-
Roche (BMC) Chemstrips	4	13	4	3
Roche (BMC) Criterion Analyzer	-	3	-	-
Roche (BMC) Mini UA	-	1	-	-
Roche Mditron	-	1	-	-
Roche Urisys	3	4	1	-
Roche(BMC) SuperUA/ChemstripUA	-	3	-	-
Thermo BioStar PocketChem UA	-	-	2	-
UriScan Reagent Strips	-	2	2	-

**URINALYSIS DIPSTICK–UROBILINOGEN**

**Specimen UA-3**

*Participant Results*

<u>Method</u>	<u>0.2/Normal mg/dL</u>	<u>1.0 mg/dL</u>	<u>2.0 mg/dL</u>	<u>4.0 mg/dL</u>	<u>&gt;8.0 mg/dL</u>
ALL METHODS	70	16	3	7	1
Arkray Aution Jet	1	-	-	-	-
Arkray Aution Sticks	1	-	2	-	-
Bayer Clinitek 50	5	1	-	-	-
Bayer Clinitek 500	20	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	7	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	8	10	1	5	1
Roche (BMC) Criterion Analyzer	2	1	-	-	-
Roche (BMC) Mini UA	-	1	-	-	-
Roche Miditron	1	-	-	-	-
Roche Urisys	4	2	-	2	-
Roche(BMC) SuperUA/ChemstripUA	2	1	-	-	-
Thermo BioStar PocketChem UA	2	-	-	-	-
UriScan Reagent Strips	4	-	-	-	-

**URINALYSIS DIPSTICK–BLOOD/HEMOGLOBIN**

**Specimen UA-3**

*Participant Results*

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	73	1	15	3	2
Arkray Aution Jet	1	-	-	-	-
Arkray Aution Sticks	3	-	-	-	-
Bayer Clinitek 50	5	-	-	-	1
Bayer Clinitek 500	19	-	-	-	-
Bayer Clinitek Atlas	5	-	-	-	-
Bayer Clinitek Status	1	-	-	-	-
Bayer Reagent Strips	7	-	-	-	-
BioScan Reagent Strips	1	-	-	-	-
Quidel QuickVue UrinChek	-	-	-	1	-
Roche (BMC) Chemstrips	12	-	10	1	1
Roche (BMC) Criterion Analyzer	2	-	1	-	-
Roche (BMC) Mini UA	-	-	1	-	-
Roche Miditron	-	-	1	-	-
Roche Urisys	4	-	2	1	-
Roche(BMC) SuperUA/ChemstripUA	3	-	-	-	-
Thermo BioStar PocketChem UA	2	-	-	-	-
UriScan Reagent Strips	4	-	-	-	-

## URINALYSIS DIPSTICK–LEUKOCYTE ESTERASE

### Specimen UA-3

#### Participant Results

<u>Method</u>	<u>Negative</u>	<u>Trace</u>	<u>Small (1+)</u>	<u>Moderate (2+)</u>	<u>Large (3+)</u>
ALL METHODS	2	-	-	6	88
Arkray Aution Sticks	-	-	-	-	3
Bayer Clinitek 50	1	-	-	1	4
Bayer Clinitek 500	-	-	-	2	18
Bayer Clinitek Atlas	-	-	-	-	5
Bayer Clinitek Status	-	-	-	-	1
Bayer Reagent Strips	-	-	-	3	4
BioScan Reagent Strips	-	-	-	-	1
Quidel QuickVue UrinChek	1	-	-	-	-
Roche (BMC) Chemstrips	-	-	-	-	25
Roche (BMC) Criterion Analyzer	-	-	-	-	3
Roche (BMC) Mini UA	-	-	-	-	1
Roche Miditron	-	-	-	-	1
Roche Urisys	-	-	-	-	8
Roche(BMC) SuperUA/ChemstripUA	-	-	-	-	3
Thermo BioStar PocketChem UA	-	-	-	-	2
UriScan Reagent Strips	-	-	-	-	4

## URINALYSIS DIPSTICK–NITRITE

### Specimen UA-3

#### Participant Results

<u>Method</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	2	95
Arkray Aution Jet	-	1
Arkray Aution Sticks	-	3
Bayer Clinitek 50	-	6
Bayer Clinitek 500	-	20
Bayer Clinitek Atlas	-	5
Bayer Clinitek Status	-	1
Bayer Reagent Strips	-	7
BioScan Reagent Strips	-	1
Quidel QuickVue UrinChek	1	-
Roche (BMC) Chemstrips	-	25
Roche (BMC) Criterion Analyzer	-	3
Roche (BMC) Mini UA	-	1
Roche Miditron	-	1
Roche Urisys	-	8
Roche(BMC) SuperUA/ChemstripUA	-	3
Thermo BioStar PocketChem UA	-	2
UriScan Reagent Strips	1	3

**URINALYSIS –MICROALBUMIN (dipstick only)****Specimen UA-3***Participant Results*

<u>Method</u>	<u>Negative</u>	<u>10 mg/L(Pos)</u>	<u>20/30 mg/L</u>	<u>50 mg/L (+)</u>	<u>80 mg/L</u>	<u>100 mg/L (++)</u>	<u>150 mg/L</u>
ALL METHODS	3	1	-	-	-	-	-
Roche (BMC) Chemstrips	1	-	-	-	-	-	-
Roche (BMC) Micral - 1 minute	1	-	-	-	-	-	-

**URINALYSIS –URINE hCG****Specimen UA-3***Participant Results*

<u>Method</u>	<u>Sensitivity (mIU/mL)</u>	<u>Negative</u>	<u>Positive</u>
ALL METHODS	-	13	-
bioMerieux VIKIA hCG-D	20	6	-
Stanbio QuPID	25	1	-
Stanbio QuPID Plus	-	1	-

**ANTIMICROBIAL SUSCEPTIBILITY TESTING**

**Specimen SUS-6**

<u>Antimicrobial</u>	-----Agar Diffusion-----				-----MIC-----				<u>Acceptable (%)</u>
	<u>Interpretative category data</u>				<u>Interpretative category data</u>				
	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	<u>Labs</u>	<u>S</u>	<u>I</u>	<u>R</u>	
Amikacin	5	5	-	-	3	3	-	-	100%
Amoxicillin/Clavulanate	2	2	-	-	15	13	-	2	89.66%
Ampicillin	9	5	-	4	14	11	-	3	Not graded <sup>1</sup>
Ampicillin/Sulbactam	6	6	-	-	5	4	-	1	89.47%
Aztreonam	2	1	-	1	-	-	-	-	Not graded <sup>1</sup>
Carbenicillin	1	1	-	-	-	-	-	-	100%
Cefaclor	1	1	-	-	-	-	-	-	100%
Cefazolin	-	-	-	-	15	13	-	2	85.19%
Cefotaxime	2	2	-	-	9	9	-	-	100%
Cefoxitin	2	2	-	-	-	-	-	-	100%
Ceftazidime	-	-	-	-	1	1	-	-	100%
Ceftriaxone	2	1	1	-	1	1	-	-	Not graded <sup>1</sup>
Cefuroxime	2	2	-	-	8	8	-	-	100%
Cephalexin	1	1	-	-	-	-	-	-	100%
Cephalothin	5	5	-	-	8	8	-	-	100%
Ciprofloxacin	9	7	1	1	18	18	-	-	95.24%
Clindamycin	8	7	-	1	14	14	-	-	93.94%
Erythromycin	5	2	1	2	3	3	-	-	Not graded <sup>1</sup>
Gentamicin	9	8	-	1	18	18	-	-	97.50%
Imipenem	2	2	-	-	7	7	-	-	100%
Kanamycin	1	1	-	-	-	-	-	-	100%
Levofloxacin	-	-	-	-	4	4	-	-	100%
Linezolid	-	-	-	-	3	3	-	-	100%
Meropenem	-	-	-	-	4	4	-	-	100%
Methicillin	1	1	-	-	-	-	-	-	100%
Nalidixic Acid	5	3	-	2	-	-	-	-	Not graded <sup>1</sup>
Nitrofurantoin	8	7	1	-	19	18	1	-	92.11%
Norfloxacin	8	8	-	-	9	9	-	-	100%
Ofloxacin	1	1	-	-	8	7	-	1	92.31%
Oxacillin	9	8	-	1	20	18	-	2	90.24%
Penicillin-G	3	2	-	1	15	12	-	3	Not graded <sup>1</sup>
Piperacillin	-	-	-	-	1	1	-	-	100%
Piperacillin/Tazobactam	-	-	-	-	1	1	-	-	100%
Rifampin	2	2	-	-	1	1	-	-	100%
Teicoplanin	-	-	-	-	3	3	-	-	100%
Tetracycline	2	1	-	1	16	16	-	-	96.77%
Ticarcillin/Clavulanate	-	-	-	-	6	6	-	-	88.89%
Tobramycin	-	-	-	-	1	-	1	-	Not graded <sup>1</sup>
Trimethoprim	1	1	-	-	3	3	-	-	100%
Trimethoprim/Sulfamethoxazole	12	10	-	2	21	21	-	-	95.65%
Vancomycin	9	6	2	1	16	16	-	-	89.47%

Organism present in specimen SUS-6: *Staphylococcus aureus*.

<sup>1</sup> This is an ungraded challenge due to less than 80% participant consensus.

## PARASITOLOGY (PA Specimens)

### Specimen PA-11

No participants reported PA-11.

Parasite present in specimen PA-11: *Entamoeba histolytica*.

### Specimen PA-12

No participants reported PA-12.

Parasite present in specimen PA-12: *Giardia lamblia*.

### Specimen PA-13

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Parasite larvae seen but no ID	1	100%	Unacceptable

Parasite present in specimen PA-13: No parasites present.

### Specimen PA-14

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Trichuris trichiura eggs	1	100%	Acceptable

Parasite present in specimen PA-14: *Trichuris trichiura* eggs.

### Specimen PA-15

No participants reported PA-15.

Parasite present in specimen PA-15: *Loa loa*.

## PARASITOLOGY (FP Specimens)

### Specimen FP-11

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Entamoeba histolytica	78	60.94%	Acceptable
Entamoeba coli	25	19.53%	Acceptable
Endolimax nana	8	6.25%	
Iodamoeba butschlii	7	5.47%	
Blastocystis hominis	5	3.91%	
Entamoeba hartmanni	2	1.56%	
Giardia lamblia	1	0.78%	
Trypanosoma gambiense	1	0.78%	
Ascaris lumbricoides eggs	1	0.78%	

Parasite present in specimen FP-11: *Entamoeba histolytica*.

### Specimen FP-12

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Ascaris lumbricoides eggs	62	50.41%	Acceptable
Trichuris trichiura eggs	33	26.83%	Acceptable
Parasite seen but no ID	1	0.81%	Acceptable
Hymenolepis nana eggs	10	8.13%	
No parasite seen	8	6.50%	
Strongyloides stercoralis	3	2.44%	
Endolimax nana	3	2.44%	
Hymenolepis diminuta eggs	1	0.81%	
Taenia sp. eggs	1	0.81%	
Blastocystis hominis	1	0.81%	

Parasites present in specimen FP-12: *Ascaris lumbricoides* eggs and *Trichuris trichiura* eggs.

### Specimen FP-13

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
No parasite seen	45	54.88%	Acceptable
Strongyloides stercoralis	28	34.15%	
Parasite larva seen but no ID	5	6.10%	
Parasite egg seen but no ID	1	1.22%	
Chilomastix mesnili	1	1.22%	
Entamoeba histolytica	1	1.22%	
Hymenolepis nana eggs	1	1.22%	

Parasite present in specimen FP-13: No parasites presents; root hairs present.

**PARASITOLOGY (FP Specimens)**

**Specimen FP-14**

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Hymenolepis nana eggs	47	52.22%	Acceptable
No parasite seen	14	15.56%	
Taenia sp. eggs	14	15.56%	
Hymenolepis diminuta eggs	8	8.89%	
Ascaris lumbricoides eggs	3	3.33%	
Endolimax nana	1	1.11%	
Hookworm	1	1.11%	
Paragonimus westermani eggs	1	1.11%	
Trichostrongylus sp. eggs	1	1.11%	

Parasite present in specimen FP-14: *Hymenolepis nana* eggs.

**Specimen FP-15**

<u>Identification</u>	<u>Labs</u>	<u>Percent</u>	<u>Performance</u>
Microfilaria-Loa loa	7	8.24%	Acceptable
Microfilaria, NOS	10	11.76%	Acceptable
No parasite seen	50	58.82%	Acceptable
Plasmodium falciparum	6	7.06%	
Plasmodium sp., NOS	4	4.71%	
Trypanosoma gambiense	2	2.35%	
Plasmodium malariae	2	2.35%	
Plasmodium vivax	1	1.18%	
Microfilaria-Wuchereria bancrofti	1	1.18%	
Microfilaria-Brugia malayi	1	1.18%	
Microfilaria-Mansonella perstans	1	1.18%	

Parasite present in specimen FP-15: *Loa loa* (1 per slide).

**Syphilis Serology—Qualitative: VDRL Slide**

<u>Method</u>	<u>Specimen SY-11</u>			<u>Specimen SY-12</u>			<u>Specimen SY-13</u>		
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	11	-	-	8	3	-	9	2	-
BioBacter	2	-	-	1	1	-	1	1	-
Wiener Lab	8	-	-	7	1	-	7	1	-
<u>Method</u>	<u>Specimen SY-14</u>			<u>Specimen SY-15</u>					
	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Weakly Reactive</u>	<u>Non-Reactive</u>			
ALL METHODS	-	-	11	-	-	11			
BioBacter	-	-	2	-	-	2			
Wiener Lab	-	-	8	-	-	8			

**Syphilis Serology—Quantitative: VDRL Slide Titer**

<u>Specimen/Method</u>	<u>0 dils</u>	<u>1 dil</u>	<u>2 dils</u>	<u>4 dils</u>	<u>8 dils</u>	<u>16 dils</u>	<u>32 dils</u>	<u>&gt;32 dils</u>
<b>Specimen SY-11</b>								
ALL METHODS	-	-	-	3	6	-	-	-
BioBacter	-	-	-	1	1	-	-	-
Wiener Lab	-	-	-	2	5	-	-	-
<b>Specimen SY-12</b>								
ALL METHODS	-	4	2	4	-	-	-	-
BioBacter	-	1	1	-	-	-	-	-
Wiener Lab	-	3	1	4	-	-	-	-
<b>Specimen SY-13</b>								
ALL METHODS	-	3	4	3	-	-	-	-
BioBacter	-	1	1	-	-	-	-	-
Wiener Lab	-	2	3	3	-	-	-	-

**Syphilis Serology—Qualitative: MHA-TP**

<u>Method</u>	<u>Specimen SY-11</u>		<u>Specimen SY-12</u>		<u>Specimen SY-13</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	3	-	2	1	3	-
Human	1	-	1	-	1	-
Serodia	1	-	1	-	1	-
<hr/>						
	<u>Specimen SY-14</u>		<u>Specimen SY-15</u>			
ALL METHODS	1	2	1	2		
Human	-	1	-	1		
Serodia	-	1	-	1		

**Syphilis Serology—Qualitative: FTA-ABS (*Treponema pallidum* Antibodies)**

<u>Method</u>	<u>Specimen SY-11</u>		<u>Specimen SY-12</u>		<u>Specimen SY-13</u>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	5	-	5	-	5	-
bioMerieux	1	-	1	-	1	-
<hr/>						
	<u>Specimen SY-14</u>		<u>Specimen SY-15</u>			
ALL METHODS	4	1	4	1		
bioMerieux	1	-	1	-		

**Syphilis Serology—Qualitative: RPR**

<u>Method</u>	<b>Specimen SY-11</b>		<b>Specimen SY-12</b>		<b>Specimen SY-13</b>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	20	-	18	2	18	2
Abbott Syfacard-R	2	-	2	-	2	-
Becton Dickinson	3	-	3	-	3	-
bioMerieux	3	-	3	-	3	-
Immunostics Inc.	1	-	-	1	-	1
Omega Diagnostics	2	-	2	-	2	-
Other Method Specified	3	-	2	1	2	1
SPINREACT	3	-	3	-	3	-

  

<u>Method</u>	<b>Specimen SY-14</b>		<b>Specimen SY-15</b>	
	<u>Reactive</u>	<u>Non-Reactive</u>	<u>Reactive</u>	<u>Non-Reactive</u>
ALL METHODS	-	20	-	20
Abbott Syfacard-R	-	2	-	2
Becton Dickinson	-	3	-	3
bioMerieux	-	3	-	3
Immunostics Inc.	-	1	-	1
Omega Diagnostics	-	2	-	2
Other Method Specified	-	3	-	3
SPINREACT	-	3	-	3

**Syphilis Serology—Quantitative: RPR (Titer)**

<u>Specimen/Method</u>	<u>1</u>	<u>2</u>	<u>4</u>	<u>8</u>	<u>16</u>	<u>32</u>	<u>64</u>	<u>&gt;64</u>
<b>Specimen SY-11</b>								
ALL METHODS	-	4	6	2	2	-	-	1
Abbott Syfacard-R	-	1	1	-	-	-	-	-
bioMerieux	-	1	1	-	-	-	-	-
Omega Diagnostics	-	-	-	-	1	-	-	1
SPINREACT	-	-	1	2	1	-	-	-
Wiener Lab	-	-	1	-	-	-	-	-
<b>Specimen SY-12</b>								
ALL METHODS	6	5	1	-	1	-	-	1
Abbott Syfacard-R	2	-	-	-	-	-	-	-
bioMerieux	-	1	-	-	-	-	-	-
Omega Diagnostics	-	-	1	-	-	-	-	1
SPINREACT	-	3	-	-	1	-	-	-
Wiener Lab	1	-	-	-	-	-	-	-
<b>Specimen SY-13</b>								
ALL METHODS	8	3	-	1	1	-	-	1
Abbott Syfacard-R	2	-	-	-	-	-	-	-
bioMerieux	1	-	-	-	-	-	-	-
Omega Diagnostics	-	1	-	-	-	-	-	1
SPINREACT	-	2	-	1	1	-	-	-
Wiener Lab	1	-	-	-	-	-	-	-

**Viral Markers – Anti-HBc**

<u>Method</u>	<b>Specimen VM-11</b>		<b>Specimen VM-12</b>		<b>Specimen VM-13</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	1	26	22	5	-	27
Abbott AxSYM	1	2	2	1	-	3
Abbott AxSYM - IgM	-	2	-	2	-	2
Abbott AxSYM - Total	-	8	8	-	-	8
Beckman ACCESS	-	1	-	1	-	1
DiaSorin (INCSTAR)	-	1	1	-	-	1
Roche Elecsys 1010/2010	-	3	3	-	-	3
Roche Modular Analytics	-	1	1	-	-	1
VITROS ECI	-	4	3	1	-	4
	<b>Specimen VM-14</b>		<b>Specimen VM-15</b>			
ALL METHODS	20	7	1	26		
Abbott AxSYM	3	-	-	3		
Abbott AxSYM - IgM	-	2	-	2		
Abbott AxSYM - Total	8	-	-	8		
Beckman ACCESS	-	1	-	1		
DiaSorin (INCSTAR)	-	1	-	1		
Roche Elecsys 1010/2010	2	1	1	2		
Roche Modular Analytics	1	-	-	1		
VITROS ECI	3	1	-	4		

**Viral Markers – Anti-HIV**

<u>Method</u>	<b>Specimen VM-11</b>		<b>Specimen VM-12</b>		<b>Specimen VM-13</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	40	-	40	40	-
Abbott AxSYM	-	3	-	3	3	-
Abbott AxSYM - IgM	-	1	-	1	1	-
Abbott AxSYM - Total	-	10	-	10	10	-
Bayer ADVIA Centaur	-	1	-	1	1	-
Beckman ACCESS	-	1	-	1	1	-
bioMerieux Vidas - IgM	-	1	-	1	1	-
bioMerieux Vitek, Mini Vidas	-	2	-	2	2	-
Roche Elecsys 1010/2010	-	6	-	6	6	-
Roche Modular Analytics	-	1	-	1	1	-
VITROS ECI	-	3	-	3	3	-
	<b>Specimen VM-14</b>		<b>Specimen VM-15</b>			
ALL METHODS	-	40	-	40		
Abbott AxSYM	-	3	-	3		
Abbott AxSYM - IgM	-	1	-	1		
Abbott AxSYM - Total	-	10	-	10		
Bayer ADVIA Centaur	-	1	-	1		
Beckman ACCESS	-	1	-	1		
bioMerieux Vidas - IgM	-	1	-	1		
bioMerieux Vitek, Mini Vidas	-	2	-	2		
Roche Elecsys 1010/2010	-	6	-	6		
Roche Modular Analytics	-	1	-	1		
VITROS ECI	-	3	-	3		

## Viral Markers – HAV

<u>Method</u>	<b>Specimen VM-11</b>		<b>Specimen VM-12</b>		<b>Specimen VM-13</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	2	26	27	1	1	27
Abbott Architect	-	1	1	-	-	1
Abbott AxSYM	2	2	3	1	1	3
Abbott AxSYM - IgM	-	3	3	-	-	3
Abbott AxSYM - Total	-	4	4	-	-	4
bioMerieux Vidas - IgM	-	2	2	-	-	2
bioMerieux Vitek, Mini Vidas	-	1	1	-	-	1
DiaSorin (INCSTAR)	-	1	1	-	-	1
Roche Elecsys 1010/2010	-	6	6	-	-	6
Roche Modular Analytics	-	2	2	-	-	2
VITROS Eci	-	2	2	-	-	2

  

<u>Method</u>	<b>Specimen VM-14</b>		<b>Specimen VM-15</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	16	12	3	25
Abbott Architect	1	-	-	1
Abbott AxSYM	4	-	1	3
Abbott AxSYM - IgM	-	3	-	3
Abbott AxSYM - Total	4	-	1	3
bioMerieux Vidas - IgM	-	2	-	2
bioMerieux Vitek, Mini Vidas	1	-	-	1
DiaSorin (INCSTAR)	-	1	-	1
Roche Elecsys 1010/2010	4	2	1	5
Roche Modular Analytics	1	1	-	2
VITROS Eci	-	2	-	2

Specimen VM-11: Total is non-reactive.

Specimen VM-12: Total and IgM are reactive

Specimen VM-13: Total is non-reactive.

Specimen VM-14: Total reactive and IgM is non-reactive.

Specimen VM-15: Total is non-reactive.

## Viral Markers – HBeAg

<u>Method</u>	<b>Specimen VM-11</b>		<b>Specimen VM-12</b>		<b>Specimen VM-13</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	14	-	14	-	14
Abbott AxSYM	-	1	-	1	-	1
Abbott AxSYM - Total	-	2	-	2	-	2
bioMerieux Vitek, Mini Vidas	-	2	-	2	-	2
DiaSorin (INCSTAR)	-	1	-	1	-	1
Roche Elecsys 1010/2010	-	3	-	3	-	3
VITROS Eci	-	1	-	1	-	1

  

<u>Method</u>	<b>Specimen VM-14</b>		<b>Specimen VM-15</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	-	14	-	14
Abbott AxSYM	-	1	-	1
Abbott AxSYM - Total	-	2	-	2
bioMerieux Vitek, Mini Vidas	-	2	-	2
DiaSorin (INCSTAR)	-	1	-	1
Roche Elecsys 1010/2010	-	3	-	3
VITROS Eci	-	1	-	1

**Viral Markers – HBsAb**

<b><u>Method</u></b>	<b>Specimen VM-11</b>		<b>Specimen VM-12</b>		<b>Specimen VM-13</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	-	33	-	33	-	33
Abbott Architect	-	1	-	1	-	1
Abbott AxSYM	-	5	-	5	-	5
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	6	-	6	-	6
Beckman ACCESS	-	1	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
DiaSorin (INCSTAR)	-	1	-	1	-	1
Roche Elecsys 1010/2010	-	9	-	9	-	9
Roche Modular Analytics	-	2	-	2	-	2
VITROS Eci	-	2	-	2	-	2
	<b>Specimen VM-14</b>		<b>Specimen VM-15</b>			
ALL METHODS	28	6	-	33		
Abbott Architect	1	-	-	1		
Abbott AxSYM	5	-	-	5		
Abbott AxSYM - IgM	1	-	-	1		
Abbott AxSYM - Total	6	-	-	6		
Beckman ACCESS	1	-	-	1		
bioMerieux Vitek, Mini Vidas	-	1	-	1		
DiaSorin (INCSTAR)	-	1	-	1		
Roche Elecsys 1010/2010	9	-	-	9		
Roche Modular Analytics	2	-	-	2		
VITROS Eci	2	-	-	2		

**Viral Markers – Anti-HBsAg**

<u>Method</u>	<b>Specimen VM-11</b>		<b>Specimen VM-12</b>		<b>Specimen VM-13</b>	
	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>	<u>Positive</u>	<u>Negative</u>
ALL METHODS	1	42	42	1	-	43
Abbott Architect	-	1	1	-	-	1
Abbott AxSYM	-	3	3	-	-	3
Abbott AxSYM - IgM	-	1	1	-	-	1
Abbott AxSYM - Total	1	9	9	1	-	10
Bayer ADVIA Centaur	-	1	1	-	-	1
Beckman ACCESS	-	1	1	-	-	1
bioMerieux Vitek, Mini Vidas	-	2	2	-	-	2
DiaSorin (INCSTAR)	-	1	1	-	-	1
Roche Elecsys 1010/2010	-	7	7	-	-	7
Roche Modular Analytics	-	1	1	-	-	1
VITROS Eci	-	5	5	-	-	5

  

	<b>Specimen VM-14</b>		<b>Specimen VM-15</b>	
ALL METHODS	-	43	1	42
Abbott Architect	-	1	-	1
Abbott AxSYM	-	3	-	3
Abbott AxSYM - IgM	-	1	-	1
Abbott AxSYM - Total	-	10	-	10
Bayer ADVIA Centaur	-	1	-	1
Beckman ACCESS	-	1	-	1
bioMerieux Vitek, Mini Vidas	-	2	-	2
DiaSorin (INCSTAR)	-	1	-	1
Roche Elecsys 1010/2010	-	7	1	6
Roche Modular Analytics	-	1	-	1
VITROS Eci	-	5	-	5

**Viral Markers – HCV**

<b><u>Method</u></b>	<b>Specimen VM-11</b>		<b>Specimen VM-12</b>		<b>Specimen VM-13</b>	
	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>	<b><u>Positive</u></b>	<b><u>Negative</u></b>
ALL METHODS	-	33	-	33	1	33
Abbott AxSYM	-	3	-	3	-	3
Abbott AxSYM - IgM	-	1	-	1	-	1
Abbott AxSYM - Total	-	9	-	9	-	9
Abbott IMx	-	1	-	1	-	1
Bayer ADVIA Centaur	-	2	-	2	-	2
bioMerieux Vitek, Mini Vidas	-	1	-	1	-	1
Dade Behring BEP 2000	-	1	-	1	-	1
Roche Elecsys 1010/2010	-	1	-	1	-	1
VITROS ECI	-	4	-	4	-	4
	<b>Specimen VM-14</b>		<b>Specimen VM-15</b>			
ALL METHODS	34	-	1	33		
Abbott AxSYM	3	-	-	3		
Abbott AxSYM - IgM	1	-	-	1		
Abbott AxSYM - Total	9	-	-	9		
Abbott IMx	1	-	-	1		
Bayer ADVIA Centaur	2	-	-	2		
bioMerieux Vitek, Mini Vidas	1	-	-	1		
Dade Behring BEP 2000	1	-	-	1		
Roche Elecsys 1010/2010	1	-	-	1		
VITROS ECI	4	-	-	4		



## Blood Gases – pH

<u>Method</u>	Specimen BG-11					Specimen BG-12				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	40	7.405	0.012	0.2	7.40	37	7.761	0.018	0.2	7.76
AVL OMNI	32	7.403	0.011	0.1	7.40	30	7.755	0.008	0.1	7.75
<u>Method</u>	Specimen BG-13					Specimen BG-14				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	39	6.877	0.018	0.3	6.88	38	7.548	0.011	0.1	7.55
AVL OMNI	31	6.880	0.015	0.2	6.88	32	7.545	0.008	0.1	7.54
<u>Method</u>	Specimen BG-15									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	38	7.760	0.016	0.2	7.76					
AVL OMNI	32	7.755	0.010	0.1	7.75					

## Blood Gases - pCO<sub>2</sub> (mmHg)

<u>Method</u>	Specimen BG-11					Specimen BG-12				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	40	45.25	1.32	2.9	45.4	39	12.88	0.76	5.9	12.8
AVL OMNI	32	45.50	1.16	2.6	45.6	32	12.95	0.70	5.4	12.8
<u>Method</u>	Specimen BG-13					Specimen BG-14				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	38	92.39	3.42	3.7	92.6	39	23.76	0.87	3.6	23.7
AVL OMNI	31	92.50	3.69	4.0	92.6	32	23.94	0.82	3.4	23.8
<u>Method</u>	Specimen BG-15									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	39	12.83	0.77	6.0	12.9					
AVL OMNI	31	12.89	0.55	4.2	12.9					

## Blood Gases - pO<sub>2</sub> (mmHg)

<u>Method</u>	Specimen BG-11					Specimen BG-12				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	37	101.10	9.29	9.2	101.0	33	442.69	33.31	7.5	444.0
AVL OMNI	30	101.69	9.88	9.7	102.3	26	445.98	29.00	6.5	448.5
<u>Method</u>	Specimen BG-13					Specimen BG-14				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	26	49.53	15.69	31.7	53.9	38	131.95	9.50	7.2	129.9
AVL OMNI	18	57.86	9.16	15.8	61.3	31	131.70	9.76	7.4	127.6
<u>Method</u>	Specimen BG-15									
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>					
All Method	34	441.10	34.35	7.8	441.2					
AVL OMNI	26	442.66	29.41	6.6	439.8					

**Blood Gases - Ionized Calcium (mmol/L)**

<u>Method</u>	<b>Specimen BG-11</b>					<b>Specimen BG-12</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	7	1.049	0.028	2.7	1.05	6	0.240	0.056	23.1	0.24
AVL OMNI	5	1.052	0.034	3.2	1.05	5	0.220	0.029	13.3	0.21

**Blood Gases - Chloride (mmol/L)**

<u>Method</u>	<b>Specimen BG-11</b>					<b>Specimen BG-12</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	13	96.0	3.9	4.0	96	13	120.6	3.5	2.9	121
AVL OMNI	11	95.9	3.9	4.1	96	11	120.9	3.6	3.0	121

  

<u>Method</u>	<b>Specimen BG-13</b>					<b>Specimen BG-14</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	11	69.7	3.3	4.7	71	13	120.6	3.7	3.1	121
AVL OMNI	10	69.5	3.4	4.9	71	11	120.9	3.9	3.2	121

  

<u>Method</u>	<b>Specimen BG-15</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	13	120.9	3.5	2.9	121
AVL OMNI	11	121.1	3.8	3.2	121

**Blood Gases - Potassium (mmol/L)**

<u>Method</u>	<b>Specimen BG-11</b>					<b>Specimen BG-12</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	14	4.29	0.16	3.8	4.3	13	0.98	0.38	39.0	0.9
AVL OMNI	11	4.27	0.17	3.9	4.3	11	0.89	0.25	27.7	0.9

  

<u>Method</u>	<b>Specimen BG-13</b>					<b>Specimen BG-14</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	12	9.28	0.34	3.7	9.3	14	1.56	0.20	12.8	1.6
AVL OMNI	11	9.28	0.36	3.8	9.3	11	1.50	0.16	10.7	1.6

  

<u>Method</u>	<b>Specimen BG-15</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	11	0.95	0.42	44.0	0.9
AVL OMNI	10	0.83	0.17	20.5	0.9

**Blood Gases - Sodium (mmol/L)**

<u>Method</u>	<b>Specimen BG-11</b>					<b>Specimen BG-12</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	14	132.2	2.7	2.0	131	14	168.4	3.7	2.2	168
AVL OMNI	11	132.7	2.8	2.1	133	11	168.6	4.1	2.4	168

  

<u>Method</u>	<b>Specimen BG-13</b>					<b>Specimen BG-14</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	14	85.4	2.6	3.0	87	14	159.4	3.5	2.2	158
AVL OMNI	11	86.4	2.0	2.3	87	11	159.9	3.8	2.4	160

  

<u>Method</u>	<b>Specimen BG-15</b>				
	<u>Labs</u>	<u>Mean</u>	<u>SD</u>	<u>CV</u>	<u>Median</u>
All Method	14	168.4	3.5	2.1	168
AVL OMNI	11	168.7	3.8	2.3	168

**Medical Laboratory Evaluation**

2011 Pennsylvania Avenue, NW, Suite 800

Washington, DC 20006-1813

800-338-2746 • 202-261-4500 • Fax: 202-835-0440

[www.acponline.org/mle](http://www.acponline.org/mle)